MedPath
Found 82 clinical trials|View Analysis
Sort by:

High Cannabidiol Plant Extract (BRC-001) to Improve Aromatase Inhibitor-Induced Arthralgia in Women With Breast Cancer

Phase 2
Recruiting
Conditions
Breast Adenocarcinoma
Anatomic Stage IIIA Breast Cancer AJCC v8
Estrogen Receptor-Positive Breast Carcinoma
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage 0 Breast Cancer AJCC v8
Breast Ductal Carcinoma In Situ
Progesterone Receptor-Positive Breast Carcinoma
Interventions
Procedure: Biospecimen Collection
Drug: Placebo Administration
Drug: BRC-001
Other: Questionnaire Administration
First Posted Date
2024-08-05
Last Posted Date
2024-08-23
Lead Sponsor
City of Hope Medical Center
Target Recruit Count
36
Registration Number
NCT06538389
Locations
🇺🇸

City of Hope Medical Center, Duarte, California, United States

Personalized Vaccine Immunotherapy in Combination with Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer

Phase 1
Not yet recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC V8
Anatomic Stage IA Breast Cancer AJCC V8
Anatomic Stage IB Breast Cancer AJCC V8
Anatomic Stage II Breast Cancer AJCC V8
Anatomic Stage IIB Breast Cancer AJCC V8
Anatomic Stage IIA Breast Cancer AJCC V8
Metastatic Triple-Negative Breast Carcinoma
Prognostic Stage IA Breast Cancer AJCC V8
Prognostic Stage IB Breast Cancer AJCC V8
Anatomic Stage III Breast Cancer AJCC V8
Interventions
First Posted Date
2024-03-21
Last Posted Date
2024-11-05
Lead Sponsor
Emory University
Target Recruit Count
18
Registration Number
NCT06324240
Locations
🇺🇸

Grady Health System, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States

and more 1 locations

Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer

Phase 3
Recruiting
Conditions
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Early Stage Triple-Negative Breast Carcinoma
Interventions
Procedure: Biospecimen Collection
Drug: Carboplatin
Drug: Cyclophosphamide
Drug: Docetaxel
Biological: Pembrolizumab
Drug: Doxorubicin
Other: Quality-of-Life Assessment
Drug: Paclitaxel
Other: Questionnaire Administration
Procedure: Surgical Procedure
First Posted Date
2023-07-03
Last Posted Date
2024-10-31
Lead Sponsor
SWOG Cancer Research Network
Target Recruit Count
2400
Registration Number
NCT05929768
Locations
🇺🇸

Northwestern Medicine Cancer Center Warrenville, Warrenville, Illinois, United States

🇺🇸

Cedars Sinai Medical Center, Los Angeles, California, United States

🇺🇸

Cancer Center of Kansas-Independence, Independence, Kansas, United States

and more 427 locations

Health Coaching-Based Navigation at the Conclusion of Treatment for the Support of Black Breast Cancer Survivors

Not Applicable
Recruiting
Conditions
Prognostic Stage IB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Interventions
Behavioral: Patient Navigation
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2023-01-06
Last Posted Date
2024-03-20
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
40
Registration Number
NCT05674578
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

STEMVAC in Patients With Early Stage Triple Negative Breast Cancer

Phase 2
Recruiting
Conditions
Anatomic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Interventions
Biological: CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Biological: Sargramostim
First Posted Date
2022-07-13
Last Posted Date
2024-11-20
Lead Sponsor
University of Washington
Target Recruit Count
33
Registration Number
NCT05455658
Locations
🇺🇸

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States

🇺🇸

Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States

🇺🇸

University of Wisconsin Carbone Cancer Center, Madison, Wisconsin, United States

A QoL Intervention for Young African American Breast Cancer Survivors

Not Applicable
Recruiting
Conditions
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage III Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIIB Breast Cancer AJCC v8
Breast Cancer
Interventions
Other: Educational Intervention
Other: Questionnaire Administration
Other: Quality-of-Life Assessment
Other: Control Intervention
First Posted Date
2022-07-11
Last Posted Date
2024-06-27
Lead Sponsor
University of Alabama at Birmingham
Target Recruit Count
30
Registration Number
NCT05452681
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer

Early Phase 1
Recruiting
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Endocrine Therapy-Induced Alopecia
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Prognostic Stage I Breast Cancer AJCC v8
Prognostic Stage IA Breast Cancer AJCC v8
Interventions
Drug: Minoxidil
Other: Quality-of-Life Assessment
Other: Questionnaire Administration
First Posted Date
2022-06-14
Last Posted Date
2024-05-31
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
50
Registration Number
NCT05417308
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Testing Laser Therapy for Treatment of Vaginal Dryness in Survivors of Breast Cancer, The Revitalize Trial

Phase 3
Not yet recruiting
Conditions
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Vaginal Atrophy
Anatomic Stage 0 Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IIIA Breast Cancer AJCC v8
Interventions
Device: Laser Therapy
Device: Sham Intervention
Other: Questionnaire Administration
Other: Quality of Life Assessment
First Posted Date
2022-05-18
Last Posted Date
2024-05-23
Lead Sponsor
Alliance for Clinical Trials in Oncology
Target Recruit Count
250
Registration Number
NCT05379153

Transcutaneous Electrical Nerve Stimulation in Chemotherapy Induced Peripheral Neuropathy in Patients With Stage I-III Early Stage Breast Cancer

Not Applicable
Recruiting
Conditions
Prognostic Stage II Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IB Breast Cancer AJCC v8
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage IA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Prognostic Stage IIIA Breast Cancer AJCC v8
Chemotherapy-Induced Peripheral Neuropathy
Early Stage Breast Carcinoma
Prognostic Stage I Breast Cancer AJCC v8
Interventions
Other: Transcutaneous Electrical Nerve Stimulation
First Posted Date
2022-05-10
Last Posted Date
2024-07-03
Lead Sponsor
Emory University
Target Recruit Count
27
Registration Number
NCT05368428
Locations
🇺🇸

Emory Saint Joseph's Hospital, Atlanta, Georgia, United States

🇺🇸

Emory University Hospital Midtown, Atlanta, Georgia, United States

🇺🇸

Emory University/Winship Cancer Institute, Atlanta, Georgia, United States

Ribociclib, Tucatinib, and Trastuzumab for the Treatment of HER2 Positive Breast Cancer

Phase 1
Recruiting
Conditions
Metastatic HER2-Positive Breast Carcinoma
Prognostic Stage IB Breast Cancer AJCC v8
Prognostic Stage IIA Breast Cancer AJCC v8
Prognostic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage IIA Breast Cancer AJCC v8
Anatomic Stage IIB Breast Cancer AJCC v8
Anatomic Stage IIIB Breast Cancer AJCC v8
Anatomic Stage IIIC Breast Cancer AJCC v8
Anatomic Stage IV Breast Cancer AJCC v8
Interventions
Other: Quality-of-Life Assessment
Drug: Fulvestrant
Drug: Carboplatin
Drug: Ribociclib
Drug: Docetaxel
Biological: Trastuzumab
Biological: Pertuzumab
Drug: Tucatinib
First Posted Date
2022-04-08
Last Posted Date
2024-04-18
Lead Sponsor
Jonsson Comprehensive Cancer Center
Target Recruit Count
18
Registration Number
NCT05319873
Locations
🇺🇸

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

© Copyright 2025. All Rights Reserved by MedPath